Refine
Has Fulltext
- yes (18)
Is part of the Bibliography
- yes (18)
Document Type
- Journal article (18)
Language
- English (18)
Keywords
- melanoma (5)
- BRAF (2)
- PD-1 (2)
- angiogenesis (2)
- immunohistochemistry (2)
- machine learning (2)
- B7-H1 Antigen (1)
- BARF-mutated melanoma (1)
- BRAF mutation (1)
- COVID-19 (1)
Institute
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (18)
- Urologische Klinik und Poliklinik (4)
- Medizinische Klinik und Poliklinik II (3)
- Pathologisches Institut (3)
- Theodor-Boveri-Institut für Biowissenschaften (3)
- Center for Computational and Theoretical Biology (2)
- Medizinische Klinik und Poliklinik I (2)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (1)
Sonstige beteiligte Institutionen
The approval of BRAF and MEK inhibitors has signifi-cantly improved treatment outcomes for patients with BRAF-mutated metastatic melanoma. The 3 first-line targeted therapy trials have provided similar results, and thus the identification of predictive biomarkers may generate a more precise basis for clinical deci-sion-making. Elevated baseline lactate dehydrogenase (LDH) has already been determined as a strong prog-nostic factor. Therefore, this indirect analysis compa-red subgroups with elevated baseline LDH across the pivotal targeted therapy trials co-BRIM, COMBI-v and COLUMBUS part 1. The Bucher method was used to compare progression-free survival, objective response rate and overall survival indirectly. The results show a non-significant risk reduction for progression in the subgroup with elevated baseline LDH receiving vemu-rafenib plus cobimetinib compared with dabrafenib plus trametinib and encorafenib plus binimetinib. Al-though an indirect comparison, these data might pro-vide some guidance for treatment recommendations in melanoma patients with elevated LDH.